Xeris Pharmaceuticals

Yahoo Finance • last year

Xeris Biopharma CEO reveals impact of CSO's departure and exciting future plans

New York --News Direct-- Xeris Biopharma Holdings Xeris Biopharma CEO Paul Edick joined Proactive's Natalie Stoberman to share the resignation of the company's Chief Scientific Officer and Founder Dr. Steven Prestrelski as he transitions... Full story

Yahoo Finance • last year

Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism

Novel formulation of levothyroxine sodium (SC injection) to potentially mitigate many of the challenges associated with oral formulations of levothyroxine. Phase 2 study to establish the average once-weekly dose, accrue additional safety... Full story

Yahoo Finance • 2 years ago

Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations

CHICAGO, April 18, 2023--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a rang... Full story

Yahoo Finance • 2 years ago

Subdued Growth No Barrier To Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) With Shares Advancing 61%

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) shares have continued their recent momentum with a 61% gain in the last month alone. But the gains over the last month weren't enough to make shareholders whole, as the share price is still down... Full story